These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 82865)

  • 1. Propranolol for renal osteodystrophy.
    Fournier A; Coevoet B; Leroux JL; de Fremont JF; Lambrey G
    Lancet; 1978 Dec 23-30; 2(8104-5):1372. PubMed ID: 82865
    [No Abstract]   [Full Text] [Related]  

  • 2. Propranolol in uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Ponticelli C
    Lancet; 1978 Oct; 2(8096):940. PubMed ID: 81949
    [No Abstract]   [Full Text] [Related]  

  • 3. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of secondary hyperparathyroidism by propranolol in renal failure patients.
    Besarab A; Caro JF; Ihle BU; Burke JF; Glennon JA; Fischer JA
    Nephron; 1981; 27(3):127-33. PubMed ID: 7219643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of renal osteodystrophy.
    Baker LR
    Miner Electrolyte Metab; 1991; 17(4):240-9. PubMed ID: 1813786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy.
    Coburn JW
    Kidney Int Suppl; 1990 Sep; 29():S54-61. PubMed ID: 2214548
    [No Abstract]   [Full Text] [Related]  

  • 7. Early dietary phosphorus restriction and calcium supplementation in the prevention of renal osteodystrophy.
    Maschio G; Tessitore N; D'Angelo A; Bonucci E; Lupo A; Valvo E; Loschiavo C; Fabris A; Morachiello P; Previato G; Fiaschi E
    Am J Clin Nutr; 1980 Jul; 33(7):1546-54. PubMed ID: 7395775
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-dose vitamin D analogues for renal osteodystrophy.
    Lancet; 1989 Jun; 1(8651):1364-5. PubMed ID: 2567378
    [No Abstract]   [Full Text] [Related]  

  • 10. Progress of renal osteodystrophy during continuous ambulatory peritoneal dialysis.
    Buccianti G; Bianchi ML; Valenti G
    Clin Nephrol; 1984 Dec; 22(6):279-83. PubMed ID: 6525771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target levels for serum phosphorus and parathyroid hormone.
    Qunibi W; Kalantar-Zadeh K
    Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
    [No Abstract]   [Full Text] [Related]  

  • 12. Control of mineral metabolism in CAPD patients.
    Delmez JA
    Blood Purif; 1989; 7(2-3):167-80. PubMed ID: 2663036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need to treat predialysis patients.
    Hamdy NA
    Nephrol Dial Transplant; 1995; 10 Suppl 4():19-22; discussion 37-43. PubMed ID: 7478145
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prophylaxis of renal osteodystrophy].
    Przedlacki J
    Pol Arch Med Wewn; 2003 Oct; 110(4):1227-34. PubMed ID: 14699682
    [No Abstract]   [Full Text] [Related]  

  • 15. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid hormone measurements in hemodialysis patients as assessments of renal osteodystrophy.
    Aubry WM; Sparks JC; Braunstein GD
    Mt Sinai J Med; 1984 Apr; 51(2):132-7. PubMed ID: 6610110
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients.
    Sharman VL; Abrams SM; Adami S; Cattell WR; Chaput de Saintonge DM; Greenwood RN; Goodwin FJ; Hately W; Hattersley LA; Marsh FP; Morgan AG; Muir JW; O'Riordan JL; Papapoulos SE; Revell P; Tucker AK; Baker LR
    Proc Eur Dial Transplant Assoc; 1983; 19():287-92. PubMed ID: 6348740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiologic vagaries of renal osteodystrophy.
    Vaisrub S
    JAMA; 1973 Jun; 224(13):1755-6. PubMed ID: 4740169
    [No Abstract]   [Full Text] [Related]  

  • 19. 1-alpha-hydroxyvitamin D3 in chronic renal failure. A potent analogue of the kidney hormone, 1,25-dihydroxycholecalciferol.
    Chan JC; Oldham SB; Holick MF; DeLuca HF
    JAMA; 1975 Oct; 234(1):47-52. PubMed ID: 1174223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylactic measures for preventing renal osteodystrophy].
    Seidel A; Ritz E
    Verh Dtsch Ges Inn Med; 1989; 95():248-52. PubMed ID: 2603483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.